Improved clinical outcomes of rhG-CSF-mobilized blood and marrow   haploidentical transplantation compared to propensity score-matched   rhG-CSF-primed peripheral blood stem cell haploidentical   transplantation: a multicenter study

doi:10.1007/s11427-016-0014-8

CORC > 北京大学 > 生命科学学院

	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study
	Zhao, Xiangyu ; Gao, Feng ; Zhang, Xiaohui ; Wang, Yu ; Xu, Lanping ; Liu, Kaiyan ; Zhao, Xiaosu ; Chang, Yingjun ; Wei, Han ; Chen, Huan ; Chen, Yuhong ; Jiang, Zhengfan ; Huang, Xiaojun
刊名	SCIENCE CHINA-LIFE SCIENCES
	2016
关键词	HBMT GPB Beijing Protocol HSCT DONOR LYMPHOCYTE INFUSION RISK HEMATOLOGIC MALIGNANCIES ACUTE-LEUKEMIA POSTTRANSPLANTATION CYCLOPHOSPHAMIDE HEMATOPOIETIC SCT PHASE-II G-PB RELAPSE PROPHYLAXIS DEPLETION
DOI	10.1007/s11427-016-0014-8
英文摘要	The effects of haploidentical rhG-CSF-mobilized blood and marrow transplantation (HBMT) on hematological malignances are well established. Previous prospective single-center studies have demonstrated better survival after HBMT versus haploidentical rhG-CSF-mobilized peripheral blood stem cell transplantation (HPBSCT) for acute leukemia (AL) not in remission (NR) or in more than the second complete remission (>CR2). To test the hypothesis that HBMT is still superior to HPBSCT for patients with AL, multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) in CR1/CR2 and for patients with chronic myeloid leukemia in the first and second chronic phase lacking a matched donor, we designed a propensity score method-based multicenter study. Hematopoietic recovery, acute graft-versus-host disease (aGVHD), and chronic GVHD were comparable between the HBMT group (n=168) and the HPBSCT group (n=42). No significant differences were found in non-relapse mortality rate (20.17%+/- 3.58% and 27.24%+/- 7.16%, P=0.18) or relapse rate (19.96%+/- 3.72% and 28.49%+/- 8.25%, P=0.32) between the HBMT group and the HPBSCT group. HBMT recipients had better overall survival (65.0%+/- 4.2% and 54.2%+/- 8.3%, P=0.037) and disease-free survival (59.9%+/- 4.6% and 44.3%+/- 8.7%, P=0.051). Multivariate analysis showed that HPBSCT was associated with poorer DFS (HR (95% CI), 1.639 (0.995-2.699), P=0.052). Our comparisons showed that HBMT was superior to HPBSCT as a post-remission treatment for patients lacking an identical donor.; National Natural Science Foundation of China [81530046, 81270644, 81230013]; Major State Basic Research Development Program of China [2013CB733700]; Collaborative Innovation Center of Hematology, Peking University, China; Beijing Talents fund [2015000021223ZK26]; Milstein Medical Asian American Partnership (MMAAP) Foundation Research Project Award in Hematology; Health Science Promotion Project of Beijing [TG-2015-003]; SCI(E); PubMed; 中国科学引文数据库(CSCD); ARTICLE; huangxiaojun@bjmu.edu.cn; 11; 1139-1148; 59
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/493261]
专题	生命科学学院
推荐引用方式 GB/T 7714	Zhao, Xiangyu,Gao, Feng,Zhang, Xiaohui,et al. Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study[J]. SCIENCE CHINA-LIFE SCIENCES,2016.
APA	Zhao, Xiangyu.,Gao, Feng.,Zhang, Xiaohui.,Wang, Yu.,Xu, Lanping.,...&Huang, Xiaojun.(2016).Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study.SCIENCE CHINA-LIFE SCIENCES.
MLA	Zhao, Xiangyu,et al."Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study".SCIENCE CHINA-LIFE SCIENCES (2016).